| What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia. | |
| | |
MedLine Citation:
|
PMID:Â 14680343 Â Â Â Owner:Â NLM Â Â Â Status:Â MEDLINE Â Â Â |
Abstract/OtherAbstract:
|
Hypertension and hyperlipidemia are potent cardiovascular risk factors. Treatment can lower blood pressure and reduce events, but the optimal drug for initial hypertension treatment and the benefits of long-term cholesterol reduction on clinical outcomes in understudied hypertensive subpopulations were unknown. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a long-term randomized, multicenter study undertaken to address these questions. In the hypertension component, 42,448 patients with mild-moderate hypertension and 1 or more other coronary risk factors were randomized to initial therapy with chlorthalidone, or to a newer antihypertensive agent--doxazosin (alpha blocker), amlodipine (calcium blocker), or lisinopril (angiotensin-converting enzyme inhibitor). The primary combined endpoint was coronary heart disease mortality or nonfatal myocardial infarction, with secondary endpoints including combinations of mortality, cardiac, and vascular complications. By interim analysis, doxazosin was shown inferior to diuretics in preventing secondary endpoints, resulting in early termination of this arm. There were no differences in primary endpoint frequency in chlorthalidone-amlodipine and chlorthalidone-lisinopril comparisons, but both amlodipine and lisinopril therapy resulted in more secondary events. In the lipid-lowering trial, 10,355 patients enrolled in the hypertensive trial with low-density-lipoprotein levels 100 to 189 mg/dL were randomized to pravastatin or usual care. There was no overall difference in the primary endpoint (total mortality) or most secondary endpoints, with statin therapy reducing stroke and coronary events modestly but nonsignificantly. Subgroup comparisons showed equivalent treatment effects in all groups except blacks, who had greater reduction in total coronary events but more strokes with pravastatin therapy and more strokes with lisinopril treatment. |
| | |
Authors:
|
Therese S Geraci; Stephen A Geraci |
Related Documents
:
|
15500433Â -Â Recent advances in the secondary prevention of coronary heart disease. 17088313Â -Â Strength of evidence for perioperative use of statins to reduce cardiovascular risk: sy... 11028143Â -Â Unjustified variations in patient management for acute myocardial infarction in the rhÃ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Review    |
Journal Detail:
|
Title: The Journal of cardiovascular nursing    Volume: 18    ISSN: 0889-4655    ISO Abbreviation: J Cardiovasc Nurs    Publication Date:   2003 Nov-Dec |
Date Detail:
|
Created Date:Â 2003-12-18 Â Â Â Completed Date:Â 2004-01-06 Â Â Â Revised Date:Â 2007-11-15 Â Â Â |
Medline Journal Info:
|
Nlm Unique ID: 8703516    Medline TA: J Cardiovasc Nurs    Country: United States    |
Other Details:
|
Languages: eng    Pagination: 389-95    Citation Subset: IM; N    |
Affiliation:
|
Research, Inc, Veterans Affairs Medical Center, Memphis, Tenn, USA. tsgeraci@aol.com |
Export Citation:
|
APA/MLA Format    Download EndNote    Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antihypertensive Agents
/
therapeutic use* Antilipemic Agents / therapeutic use* Clinical Trials as Topic Coronary Disease / epidemiology, prevention & control Humans Hyperlipidemias / drug therapy*, epidemiology* Hypertension / drug therapy*, epidemiology* Risk Assessment Risk Factors Stroke / epidemiology, prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Antilipemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Robotically assisted cardiac surgery: minimally invasive techniques to totally endoscopic heart surg...
Next Document: Steal syndrome complicating upper extremity hemoaccess procedures: incidence and risk factors.